Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

19-01-02

Domain Therapeutics wishes you Health, Happiness and Success for 2019

voeux-domain-2019.pdf 

18-12-04

Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders

Press Release 2018-12-04 

18-12-03

Pour la revue "Nature Chemical Biology" la plateforme bioSensAll peut avoir un impact important.

Découvrez l'article:

https://www.nature.com/articles/s41589-018-0160-y


18-11-19

Bel article sur Domain Therapeutics dans Biotech Finances du 19 novembre :

« DOMAIN THERAPEUTICS VEUT EXPLORER DE NOUVEAUX TERRITOIRES »

« Notre stratégie, qui consiste à transférer nos programmes dans des sociétés mono-produit ensuite financées par des investisseurs en capital-risque, nous permet de garder la maîtrise du risque dans le développement de notre portefeuille interne », précise Pascal Neuville, directeur général.

Retrouvez l’article original ici : https://www.biotech-finances.com/domain-therapeutics-biotechfinances-n-832-19-11-2018/